McGraw Patterson Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA.
McGraw Patterson Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Patient Educ Couns. 2017 Aug;100(8):1527-1536. doi: 10.1016/j.pec.2017.03.024. Epub 2017 Mar 22.
Patients often anticipate cure from palliative chemotherapy. Better resources are needed to convey its risks and benefits. We describe the stakeholder-driven development and acceptability testing of a prototype video and companion booklet supporting informed consent (IC) for a common palliative chemotherapy regimen.
Our multidisciplinary team (researchers, advocates, clinicians) employed a multistep process of content development, production, critical evaluation, and iterative revisions. Patient/clinician stakeholders were engaged throughout using stakeholder advisory panels, featuring their voices within the intervention, conducting surveys and qualitative interviews. A national panel of 57 patient advocates, and 25 oncologists from nine US practices critiqued the intervention and rated its clarity, accuracy, balance, tone, and utility. Participants also reported satisfaction with existing chemotherapy IC materials.
Few oncologists (5/25, 20%) or advocates (10/22, 45%) were satisfied with existing IC materials. In contrast, most rated our intervention highly, with 89-96% agreeing it would be useful and promote informed decisions. Patient voices were considered a key strength. Every oncologist indicated they would use the intervention regularly.
Our intervention was acceptable to advocates and oncologists. A randomized trial is evaluating its impact on the chemotherapy IC process.
Stakeholder-driven methods can be valuable for developing patient educational interventions.
患者常常期望姑息化疗能治愈疾病。需要更好的资源来传达其风险和益处。我们描述了一种支持常见姑息化疗方案知情同意(IC)的原型视频和配套手册的利益相关者驱动的开发和可接受性测试。
我们的多学科团队(研究人员、倡导者、临床医生)采用了多步骤的内容开发、制作、批判性评估和迭代修订过程。患者/临床医生利益相关者通过利益相关者咨询小组参与其中,在干预措施中体现他们的声音,进行调查和定性访谈。一个由 57 名患者倡导者和来自美国 9 个实践的 25 名肿瘤学家组成的全国小组对干预措施进行了评估,并对其清晰度、准确性、平衡性、语气和实用性进行了评分。参与者还报告了对现有化疗 IC 材料的满意度。
很少有肿瘤学家(25 名中的 5 名,20%)或倡导者(22 名中的 10 名,45%)对现有 IC 材料感到满意。相比之下,大多数人对我们的干预措施评价很高,89-96%的人认为它将是有用的,并促进知情决策。患者的声音被认为是一个关键优势。每位肿瘤学家都表示他们将经常使用该干预措施。
我们的干预措施得到了倡导者和肿瘤学家的认可。一项随机试验正在评估其对化疗 IC 过程的影响。
利益相关者驱动的方法对于开发患者教育干预措施非常有价值。